3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation - ScienceDirect
EVOLVE Short DAPT in Print: P2Y12 Decisions Can Safely Be Made Case-by-Case | tctmd.com
Managing Anticoagulation and Dual Antiplatelet Therapy in Patients with Active Bleed or Upcoming Procedure: A Scoping Review | Published in Journal of Brown Hospital Medicine
EVOLVE Short DAPT: A Single-Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated With a Bioabsorbable Polymer-Based Everolimus-Eluting Stent | tctmd.com
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
Can We Define High-risk DAPT Patients in USA Practice? - ppt download
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Davide Capodanno on X: "My editorial to the EVOLVE Short DAPT study, from @ajaykirtane and colleagues (congratulations!). Interesting result and insightful data in a rapidly changing scenario that has more to say.
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
EVOLVE Short DAPT with the SYNERGY BP Stent - YouTube
Short and Optimal DAPT: Lessons From the EVOLVE SHORT-DAPT Late Breaking Science | tctmd.com
Two further studies support three-month DAPT following PCI
BostonSci Cardiology on X: "See how SYNERGY™ BP Stent performed 12-months post-DAPT discontinuation in the EVOLVE Short #DAPT Trial: https://t.co/fQIpaJOGOC Safety Info: https://t.co/aA0ofN4r9t https://t.co/lrWq5mVKBT" / X
EVOLVE Short DAPT Trial – SYNERGY Stent - Boston Scientific
SYNERGY™ Clinical Program - Short DAPT - Boston Scientific
Session evaluation and key learnings
Bleeding and Ischemic Risk Prediction in Patients With High Bleeding Risk (an EVOLVE Short DAPT Analysis) - ScienceDirect
3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation
Evolving Concepts in Post-PCI Antiplatelets Therapy
31861-1.fp.png "SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal")
SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal
Another Coronary Stent for Patients at High Bleeding Risk∗ | JACC: Cardiovascular Interventions
Antiplatelet therapy after percutaneous coronary intervention - EuroIntervention
Two further studies support three-month DAPT following PCI
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
Studying DAPT – SYNERGY Stent - Boston Scientific
